)
MoonLake Immunotherapeutics (MLTX) investor relations material
MoonLake Immunotherapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Voting matters and shareholder proposals
Election of Class I director nominee Spike Loy to serve until the 2029 Annual General Meeting of Shareholders and until a successor is elected and qualified.
Ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Advisory approval of the compensation of named executive officers.
Approval of an amendment and restatement of the 2022 Equity Incentive Plan.
Other business may be addressed as properly brought before the meeting or any adjournments.
Board of directors and corporate governance
Shareholders are asked to elect one Class I director nominee, Spike Loy, for a term ending in 2029.
Executive compensation and say-on-pay
Shareholders will vote on a non-binding, advisory basis to approve the compensation of named executive officers.
Proposed amendment and restatement of the 2022 Equity Incentive Plan is subject to shareholder approval.
- Annual meeting to vote on director, auditor, executive pay, and equity plan amendments.MLTX
Proxy filing22 Apr 2026 - BLA submission for SLK in HS advances with robust efficacy, safety, and financial runway.MLTX
Investor Day 202623 Feb 2026 - Over 80% of axSpA patients achieved ASAS40 at week 12 in Phase 2, with strong financial runway.MLTX
Q4 202523 Feb 2026 - Phase III HS trial completed fast enrollment, with strong market and financial positioning.MLTX
CMD 20253 Feb 2026 - Advancing sonelokimab in late-stage trials, targeting $8B+ peak sales and 2027 U.S. launch.MLTX
CMD 202421 Jan 2026 - Director elections, auditor ratification, and say-on-pay headline a governance-focused agenda.MLTX
Proxy Filing2 Dec 2025 - Director elections, auditor ratification, and executive pay up for vote at June 2025 AGM.MLTX
Proxy Filing2 Dec 2025 - Net loss rose on higher R&D, but strong cash and positive trial data support outlook into 2027.MLTX
Q3 20255 Nov 2025 - Sonelokimab achieved strong phase 3 HS results, supporting a clear path to registration.MLTX
R&D Day 202529 Sep 2025
Next MoonLake Immunotherapeutics earnings date
Next MoonLake Immunotherapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)